cached image

William R. Markesbery, MD, University of Kentucky - Publications

Affiliations: 
Pathology University of Kentucky, Lexington, KY 
Area:
neurology, oxidative stress, Alzheimer disease
Website:
http://www.research.uky.edu/odyssey/spring10/markesbery.html

270 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Iacono D, Zandi P, Gross M, Markesbery WR, Pletnikova O, Rudow G, Troncoso JC. APOε2 and education in cognitively normal older subjects with high levels of AD pathology at autopsy: findings from the Nun Study. Oncotarget. 6: 14082-91. PMID 26101858 DOI: 10.18632/Oncotarget.4118  0.475
2012 Gwon AR, Park JS, Arumugam TV, Kwon YK, Chan SL, Kim SH, Baik SH, Yang S, Yun YK, Choi Y, Kim S, Tang SC, Hyun DH, Cheng A, Dann CE, ... ... Markesbery WR, et al. Oxidative lipid modification of nicastrin enhances amyloidogenic γ-secretase activity in Alzheimer's disease. Aging Cell. 11: 559-68. PMID 22404891 DOI: 10.1016/J.Jalz.2013.08.077  0.462
2012 Poon LW, Woodard JL, Stephen Miller L, Green R, Gearing M, Davey A, Arnold J, Martin P, Siegler IC, Nahapetyan L, Kim YS, Markesbery W. Understanding dementia prevalence among centenarians. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 67: 358-65. PMID 22389466 DOI: 10.1093/Gerona/Glr250  0.328
2012 Ding Q, Zhu H, Zhang B, Soriano A, Burns R, Markesbery WR. Increased 5S rRNA oxidation in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 29: 201-9. PMID 22232003 DOI: 10.3233/Jad-2012-111058  0.456
2012 Bradley MA, Xiong-Fister S, Markesbery WR, Lovell MA. Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiology of Aging. 33: 1034-44. PMID 20965613 DOI: 10.1016/J.Neurobiolaging.2010.08.016  0.472
2012 Gleichmann M, Zhang Y, Wood WH, Becker KG, Mughal MR, Pazin MJ, van Praag H, Kobilo T, Zonderman AB, Troncoso JC, Markesbery WR, Mattson MP. Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. Neurobiology of Aging. 33: 205.e1-18. PMID 20947216 DOI: 10.1016/J.Neurobiolaging.2010.08.012  0.375
2011 Robinson RA, Joshi G, Huang Q, Sultana R, Baker AS, Cai J, Pierce W, St Clair DK, Markesbery WR, Butterfield DA. Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease. Proteomics. 11: 4243-56. PMID 21954051 DOI: 10.1002/Pmic.201000523  0.389
2011 Sultana R, Robinson RA, Di Domenico F, Abdul HM, St Clair DK, Markesbery WR, Cai J, Pierce WM, Butterfield DA. Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age. Journal of Proteomics. 74: 2430-40. PMID 21726674 DOI: 10.1016/J.Jprot.2011.06.015  0.392
2011 Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, Butterfield DA. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. Journal of Alzheimer's Disease : Jad. 23: 257-69. PMID 20930294 DOI: 10.3233/Jad-2010-101083  0.453
2011 Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, Petersen RC, Turner RS, Kukull WA, Bennett DA, Galasko D, et al. Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiology of Aging. 32: 2113-22. PMID 20452100 DOI: 10.1016/J.Neurobiolaging.2010.01.010  0.47
2010 Ebenezer PJ, Weidner AM, LeVine H, Markesbery WR, Murphy MP, Zhang L, Dasuri K, Fernandez-Kim SO, Bruce-Keller AJ, Gavilán E, Keller JN. Neuron specific toxicity of oligomeric amyloid-β: role for JUN-kinase and oxidative stress. Journal of Alzheimer's Disease : Jad. 22: 839-48. PMID 20858948 DOI: 10.3233/Jad-2010-101161  0.372
2010 Huang Q, Aluise CD, Joshi G, Sultana R, St Clair DK, Markesbery WR, Butterfield DA. Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. Journal of Neuroscience Research. 88: 2618-29. PMID 20648652 DOI: 10.1002/Jnr.22422  0.439
2010 Nelson PT, Schmitt FA, Jicha GA, Kryscio RJ, Abner EL, Smith CD, Van Eldik LJ, Markesbery WR. Association between male gender and cortical Lewy body pathology in large autopsy series. Journal of Neurology. 257: 1875-81. PMID 20563821 DOI: 10.1007/S00415-010-5630-4  0.564
2010 Aluise CD, Robinson RA, Beckett TL, Murphy MP, Cai J, Pierce WM, Markesbery WR, Butterfield DA. Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiology of Disease. 39: 221-8. PMID 20399861 DOI: 10.1016/J.Nbd.2010.04.011  0.45
2010 Jicha GA, Markesbery WR. Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clinical Interventions in Aging. 5: 45-61. PMID 20396634 DOI: 10.2147/Cia.S5231  0.423
2010 Dasuri K, Ebenezer P, Zhang L, Fernandez-Kim SO, Bruce-Keller AJ, Markesbery WR, Keller JN. Increased protein hydrophobicity in response to aging and Alzheimer disease. Free Radical Biology & Medicine. 48: 1330-7. PMID 20188163 DOI: 10.1016/J.Freeradbiomed.2010.02.012  0.393
2010 Bradley MA, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radical Biology & Medicine. 48: 1570-6. PMID 20171275 DOI: 10.1016/J.Freeradbiomed.2010.02.016  0.395
2010 Bader Lange ML, St Clair D, Markesbery WR, Studzinski CM, Murphy MP, Butterfield DA. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiology of Disease. 38: 104-15. PMID 20083199 DOI: 10.1016/J.Nbd.2010.01.004  0.379
2010 Lynn BC, Wang J, Markesbery WR, Lovell MA. Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 19: 325-39. PMID 20061648 DOI: 10.3233/Jad-2010-1254  0.401
2010 Markesbery WR. Neuropathologic alterations in mild cognitive impairment: a review. Journal of Alzheimer's Disease : Jad. 19: 221-8. PMID 20061641 DOI: 10.3233/Jad-2010-1220  0.458
2010 Bruce-Keller AJ, Gupta S, Parrino TE, Knight AG, Ebenezer PJ, Weidner AM, LeVine H, Keller JN, Markesbery WR. NOX activity is increased in mild cognitive impairment. Antioxidants & Redox Signaling. 12: 1371-82. PMID 19929442 DOI: 10.1089/Ars.2009.2823  0.462
2010 Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, Xu LO, Smith CD, Markesbery WR. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. Journal of Neurology. 257: 359-66. PMID 19795154 DOI: 10.1007/S00415-009-5324-Y  0.587
2010 Lyubartseva G, Smith JL, Markesbery WR, Lovell MA. Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathology (Zurich, Switzerland). 20: 343-50. PMID 19371353 DOI: 10.1111/J.1750-3639.2009.00283.X  0.473
2010 Jicha GA, Schmitt FA, Abner E, Nelson PT, Cooper GE, Smith CD, Markesbery WR. Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiology of Aging. 31: 1805-13. PMID 19026468 DOI: 10.1016/J.Neurobiolaging.2008.09.017  0.614
2010 Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Davis DG, Poduska JW, Patel E, Mendiondo MS, Markesbery WR. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathology (Zurich, Switzerland). 20: 66-79. PMID 19021630 DOI: 10.1111/J.1750-3639.2008.00244.X  0.592
2010 Jo DG, Arumugam TV, Woo HN, Park JS, Tang SC, Mughal M, Hyun DH, Park JH, Choi YH, Gwon AR, Camandola S, Cheng A, Cai H, Song W, Markesbery WR, et al. Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease. Neurobiology of Aging. 31: 917-25. PMID 18687504 DOI: 10.1016/J.Neurobiolaging.2008.07.003  0.384
2009 Grear KE, Ling IF, Simpson JF, Furman JL, Simmons CR, Peterson SL, Schmitt FA, Markesbery WR, Liu Q, Crook JE, Younkin SG, Bu G, Estus S. Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Molecular Neurodegeneration. 4: 46. PMID 19889229 DOI: 10.1186/1750-1326-4-46  0.419
2009 Nelson PT, Kryscio RJ, Jicha GA, Abner EL, Schmitt FA, Xu LO, Cooper G, Smith CD, Markesbery WR. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology. 73: 1127-33. PMID 19805729 DOI: 10.1212/Wnl.0B013E3181Bacf9E  0.615
2009 Iacono D, Markesbery WR, Gross M, Pletnikova O, Rudow G, Zandi P, Troncoso JC. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology. 73: 665-73. PMID 19587326 DOI: 10.1212/Wnl.0B013E3181B01077  0.453
2009 Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Santacruz K, Smith CD, Patel E, Markesbery WR. Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. Journal of Neuropathology and Experimental Neurology. 68: 774-84. PMID 19535994 DOI: 10.1097/Nen.0B013E3181Aacbe9  0.601
2009 Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. Journal of Neuropathology and Experimental Neurology. 68: 816-22. PMID 19535990 DOI: 10.1097/Nen.0B013E3181Ac10A7  0.416
2009 Mortimer JA, Snowdon DA, Markesbery WR. The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Disease and Associated Disorders. 23: 152-7. PMID 19484916 DOI: 10.1097/Wad.0B013E318190A855  0.442
2009 Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging. 30: 1026-36. PMID 19376612 DOI: 10.1016/J.Neurobiolaging.2009.04.002  0.465
2009 Reed TT, Pierce WM, Markesbery WR, Butterfield DA. Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Research. 1274: 66-76. PMID 19374891 DOI: 10.1016/J.Brainres.2009.04.009  0.472
2009 Lovell MA, Xiong S, Lyubartseva G, Markesbery WR. Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free Radical Biology & Medicine. 46: 1527-33. PMID 19303433 DOI: 10.1016/J.Freeradbiomed.2009.03.008  0.319
2009 Nelson PT, Kryscio RJ, Abner EL, Schmitt FA, Jicha GA, Mendiondo MS, Cooper G, Smith CB, Markesbery WR. Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLB. Journal of Alzheimer's Disease : Jad. 16: 29-34. PMID 19158418 DOI: 10.3233/Jad-2009-0926  0.616
2009 Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. Journal of Neuropathology and Experimental Neurology. 68: 1-14. PMID 19104448 DOI: 10.1097/Nen.0B013E3181919A48  0.618
2009 Studzinski CM, Li F, Bruce-Keller AJ, Fernandez-Kim SO, Zhang L, Weidner AM, Markesbery WR, Murphy MP, Keller JN. Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP x PS1 knock-in mice. Journal of Neurochemistry. 108: 860-6. PMID 19046405 DOI: 10.1111/J.1471-4159.2008.05798.X  0.357
2009 Nelson PT, Abner EL, Scheff SW, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Patel E, Markesbery WR. Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. Neuroscience Letters. 450: 336-9. PMID 19010392 DOI: 10.1016/J.Neulet.2008.11.006  0.613
2009 Nelson PT, Smith CD, Abner EA, Schmitt FA, Scheff SW, Davis GJ, Keller JN, Jicha GA, Davis D, Wang-Xia W, Hartman A, Katz DG, Markesbery WR. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochimica Et Biophysica Acta. 1792: 454-69. PMID 18789386 DOI: 10.1016/J.Bbadis.2008.08.005  0.511
2009 Reed TT, Pierce WM, Turner DM, Markesbery WR, Butterfield DA. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. Journal of Cellular and Molecular Medicine. 13: 2019-29. PMID 18752637 DOI: 10.1111/J.1582-4934.2008.00478.X  0.473
2009 Tyas SL, Snowdon DA, Desrosiers MF, Riley KP, Markesbery WR. O2-02-01: Early-life linguistic ability, late-life pathology and asymptomatic Alzheimer's disease: Findings from the Nun Study Alzheimer's & Dementia. 5: P103-P104. DOI: 10.1016/J.Jalz.2009.05.325  0.331
2009 Jicha GA, Abner E, Schmitt FA, Markesbery WR. P4-096: Preclinical Alzheimer's disease cannot be reliably identified in the antemortem setting using standard clinical and neuropsychological test measures Alzheimer's & Dementia. 5: P459-P459. DOI: 10.1016/J.Jalz.2009.04.865  0.347
2009 Schmitt FA, Kryscio RJ, Xu L, Mendiondo M, Caban-Holt A, Abner E, Runyons C, Markesbery WR. P1-277: Effects of repeated screening and potential impact on AD prevention trial design: The antioxidant AD prevention (PREADVISE) trial Alzheimer's & Dementia. 5: P258-P258. DOI: 10.1016/J.Jalz.2009.04.285  0.347
2009 Mortimer JA, Snowdon DA, Markesbery WR. P3-118: Larger head circumference and greater education provide protection against incident dementia independent of the severity of Alzheimer pathology: The Nun Study Alzheimer's & Dementia. 5: P379-P379. DOI: 10.1016/J.Jalz.2009.04.1093  0.362
2008 Dong J, Robertson JD, Markesbery WR, Lovell MA. Serum zinc in the progression of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 15: 443-50. PMID 18997297 DOI: 10.3233/Jad-2008-15310  0.377
2008 Smith CD, Chebrolu H, Markesbery WR, Liu J. Improved predictive model for pre-symptomatic mild cognitive impairment and Alzheimer's disease. Neurological Research. 30: 1091-6. PMID 18768112 DOI: 10.1179/174313208X327973  0.347
2008 Abdul HM, Sultana R, St Clair DK, Markesbery WR, Butterfield DA. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radical Biology & Medicine. 45: 1420-5. PMID 18762245 DOI: 10.1016/J.Freeradbiomed.2008.08.012  0.4
2008 Jicha GA, Abner E, Schmitt FA, Cooper GE, Stiles N, Hamon R, Carr S, Smith CD, Markesbery WR. Clinical features of mild cognitive impairment differ in the research and tertiary clinic settings. Dementia and Geriatric Cognitive Disorders. 26: 187-92. PMID 18724049 DOI: 10.1159/000151635  0.324
2008 Shao C, Xiong S, Li GM, Gu L, Mao G, Markesbery WR, Lovell MA. Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radical Biology & Medicine. 45: 813-9. PMID 18598755 DOI: 10.1016/J.Freeradbiomed.2008.06.003  0.451
2008 Tang SC, Lathia JD, Selvaraj PK, Jo DG, Mughal MR, Cheng A, Siler DA, Markesbery WR, Arumugam TV, Mattson MP. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Experimental Neurology. 213: 114-21. PMID 18586243 DOI: 10.1016/J.Expneurol.2008.05.014  0.331
2008 Mortimer JA, Snowdon DA, Markesbery WR. Small head circumference is associated with less education in persons at risk for Alzheimer disease in later life. Alzheimer Disease and Associated Disorders. 22: 249-54. PMID 18580587 DOI: 10.1097/Wad.0B013E318170D455  0.412
2008 Sonnen JA, Breitner JC, Lovell MA, Markesbery WR, Quinn JF, Montine TJ. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radical Biology & Medicine. 45: 219-30. PMID 18482592 DOI: 10.1016/J.Freeradbiomed.2008.04.022  0.336
2008 Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology. 70: 2212-8. PMID 18448869 DOI: 10.1212/01.Wnl.0000312383.39973.88  0.364
2008 Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiology of Disease. 30: 107-20. PMID 18325775 DOI: 10.1016/J.Nbd.2007.12.007  0.449
2008 Lovell MA, Markesbery WR. Oxidatively modified RNA in mild cognitive impairment. Neurobiology of Disease. 29: 169-75. PMID 17920285 DOI: 10.1016/J.Nbd.2007.07.030  0.437
2008 Petrovitch H, Ross GW, He Q, Uyehara-Lock J, Markesbery W, Davis D, Nelson J, Masaki K, Launer L, White LR. Characterization of Japanese-American men with a single neocortical AD lesion type. Neurobiology of Aging. 29: 1448-55. PMID 17499884 DOI: 10.1016/J.Neurobiolaging.2007.03.026  0.396
2008 Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiology of Aging. 29: 1587-90. PMID 17466414 DOI: 10.1016/J.Neurobiolaging.2007.03.008  0.431
2008 Iacono D, Pletnikova O, Patel E, Tudor D, Markesbery WR, Zandi P, Troncoso JC, Snowdon D. P1-393: Hypertrophy of CA1-hippocampal neurons and APOE frequency in asymptomatic Alzheimer's disease: Findings from the Nun Study Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.974  0.359
2008 Schmitt FA, Caban-Holt A, Abner EL, Runyons C, Kryscio R, Mendiondo M, Markesbery WR. P4-393: Memory screening validation for Alzheimer prevention trials: The prevention of Alzheimer's disease by vitamin E and selenium (PREADVISE) study Alzheimer's & Dementia. 4: T789-T790. DOI: 10.1016/J.Jalz.2008.05.2463  0.35
2008 Jicha GA, Abner E, Schmitt FA, Nelson PT, Davis D, Markesbery WR. P4-155: Preclinical Alzheimer's disease in a large autopsy series of longitudinally studied, cognitively normal control subjects Alzheimer's & Dementia. 4: T715-T716. DOI: 10.1016/J.Jalz.2008.05.2222  0.567
2008 White LR, Petrovitch H, Ross W, Ueyhara-Lock JH, Masaki K, McMurtray A, Yun S, Markesbery W. P4-128: Aging-related primary brain atrophy: Frequency, association with dementia, and risk factors in the Honolulu-Asia Aging Study Alzheimer's & Dementia. 4: T707-T708. DOI: 10.1016/J.Jalz.2008.05.2194  0.32
2008 Schlosser G, Keller JD, Scheff SW, Smith CD, Cooper GE, Stiles N, Frederick SA, Markesbery WR, Jicha GA. P4-104: Metabolic dysregulation is associated with the development of mild cognitive impairment and Alzheimer's disease Alzheimer's & Dementia. 4: T699-T699. DOI: 10.1016/J.Jalz.2008.05.2170  0.37
2008 Tyas SL, Snowdon DA, Desrosiers MF, Riley KP, Markesbery WR. P4-054: Cerebral cortical atrophy, brain infarcts, and clinical expression of Alzheimer pathology: Findings from The Nun Study Alzheimer's & Dementia. 4: T684-T684. DOI: 10.1016/J.Jalz.2008.05.2119  0.368
2008 Mendiondo MS, Kryscio RJ, Abner EL, Caban-Holt AM, Runyons C, Markesbery WR, Schmitt FA. P3-159: Practice effects: Factors associated with repeated memory impairment screen scores in the antioxidant Alzheimer's disease prevention (PREADVISE) trial Alzheimer's & Dementia. 4: T566-T567. DOI: 10.1016/J.Jalz.2008.05.1725  0.342
2007 Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, Abner EL, Markesbery WR. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. Journal of Neuropathology and Experimental Neurology. 66: 1136-46. PMID 18090922 DOI: 10.1097/Nen.0B013E31815C5Efb  0.632
2007 Youn H, Ji I, Ji HP, Markesbery WR, Ji TH. Under-expression of Kalirin-7 Increases iNOS activity in cultured cells and correlates to elevated iNOS activity in Alzheimer's disease hippocampus. Journal of Alzheimer's Disease : Jad. 12: 271-81. PMID 18057561 DOI: 10.3233/Jad-2007-12309  0.413
2007 Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Research. 35: 7497-504. PMID 17947327 DOI: 10.1093/Nar/Gkm821  0.388
2007 Tyas SL, Snowdon DA, Desrosiers MF, Riley KP, Markesbery WR. Healthy ageing in the Nun Study: definition and neuropathologic correlates. Age and Ageing. 36: 650-5. PMID 17906306 DOI: 10.1093/Ageing/Afm120  0.348
2007 Youn H, Jeoung M, Koo Y, Ji H, Markesbery WR, Ji I, Ji TH. Kalirin is under-expressed in Alzheimer's disease hippocampus. Journal of Alzheimer's Disease : Jad. 11: 385-97. PMID 17851188 DOI: 10.3233/Jad-2007-11314  0.42
2007 Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA, Reiman EM, Kowall N, Landreth G, Shelanski M, Welsh-Bohmer K, ... ... Markesbery W, et al. The National Alzheimer's Coordinating Center (NACC) database: The uniform data set Alzheimer Disease and Associated Disorders. 21: 249-258. PMID 17804958 DOI: 10.1097/Wad.0B013E318142774E  0.45
2007 Weissman L, Jo DG, Sørensen MM, de Souza-Pinto NC, Markesbery WR, Mattson MP, Bohr VA. Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Research. 35: 5545-55. PMID 17704129 DOI: 10.1093/Nar/Gkm605  0.447
2007 Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H, Keller JN. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiology of Disease. 27: 301-11. PMID 17651976 DOI: 10.1016/J.Nbd.2007.06.002  0.438
2007 Markesbery WR, Lovell MA. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Archives of Neurology. 64: 954-6. PMID 17620484 DOI: 10.1001/Archneur.64.7.954  0.395
2007 Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. Journal of Neuroscience Research. 85: 3036-40. PMID 17510979 DOI: 10.1002/Jnr.21346  0.467
2007 Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR. Brain structural alterations before mild cognitive impairment. Neurology. 68: 1268-73. PMID 17438217 DOI: 10.1212/01.Wnl.0000259542.54830.34  0.399
2007 Mao G, Pan X, Zhu BB, Zhang Y, Yuan F, Huang J, Lovell MA, Lee MP, Markesbery WR, Li GM, Gu L. Identification and characterization of OGG1 mutations in patients with Alzheimer's disease. Nucleic Acids Research. 35: 2759-66. PMID 17426120 DOI: 10.1093/Nar/Gkm189  0.435
2007 Butterfield DA, Reed TT, Perluigi M, De Marco C, Coccia R, Keller JN, Markesbery WR, Sultana R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Research. 1148: 243-8. PMID 17395167 DOI: 10.1016/J.Brainres.2007.02.084  0.491
2007 Xiong S, Markesbery WR, Shao C, Lovell MA. Seleno-L-methionine protects against beta-amyloid and iron/hydrogen peroxide-mediated neuron death. Antioxidants & Redox Signaling. 9: 457-67. PMID 17280487 DOI: 10.1089/Ars.2006.1363  0.319
2007 Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, Taylor JP, Kretzschmar HA, Kimonis VE, Forman MS. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. Journal of Neuropathology and Experimental Neurology. 66: 152-7. PMID 17279000 DOI: 10.1096/Fasebj.21.5.A25  0.336
2007 Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Markesbery WR. Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly. Neurobiology of Aging. 28: 1075-87. PMID 16774798 DOI: 10.1016/J.Neurobiolaging.2006.05.018  0.326
2007 Schmitt FA, Kryscio RJ, Caban-Holt A, Abner EL, Runyons C, Mendiondo M, Bottigi K, Markesbery WR. P-118: Concordance of MIS and CERAD screening in the preadvise antioxidant AD prevention trial Alzheimer's & Dementia. 3: S136-S136. DOI: 10.1016/J.Jalz.2007.04.182  0.33
2007 Schmitt FA, Kryscio RJ, Abner EL, Mendiondo MS, Runyons C, Caban-Holt A, Markesbery WR. P-200: Factors associated with practice effects and decline in MIS scores in the preadvise antioxidant Alzheimer's disease prevention trial Alzheimer's & Dementia. 3: S162-S162. DOI: 10.1016/J.Jalz.2007.04.163  0.363
2006 Markesbery WR. Commentary on "Vascular cognitive impairment: today and tomorrow". Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 205-6. PMID 19595887 DOI: 10.1016/J.Jalz.2006.04.004  0.353
2006 Markesbery WR, Lovell MA. DNA oxidation in Alzheimer's disease. Antioxidants & Redox Signaling. 8: 2039-45. PMID 17034348 DOI: 10.1089/Ars.2006.8.2039  0.381
2006 Lovell MA, Markesbery WR. Amyloid beta peptide, 4-hydroxynonenal and apoptosis. Current Alzheimer Research. 3: 359-64. PMID 17017866 DOI: 10.2174/156720506778249506  0.371
2006 Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, Jhaveri BS, Karlawish JH, Pestronk A, Smith TW, Tu PH, Watts GD, Markesbery WR, Smith CD, Kimonis VE. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. Journal of Neuropathology and Experimental Neurology. 65: 571-81. PMID 16783167 DOI: 10.1097/00005072-200606000-00005  0.312
2006 Lovell MA, Smith JL, Markesbery WR. Elevated zinc transporter-6 in mild cognitive impairment, Alzheimer disease, and pick disease. Journal of Neuropathology and Experimental Neurology. 65: 489-98. PMID 16772872 DOI: 10.1097/01.Jnen.0000229237.98124.91  0.455
2006 Ding Q, Markesbery WR, Cecarini V, Keller JN. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochemical Research. 31: 705-10. PMID 16770743 DOI: 10.1007/S11064-006-9071-5  0.38
2006 Liu M, Sun A, Shin EJ, Liu X, Kim SG, Runyons CR, Markesbery W, Kim HC, Bing G. Expression of microsomal epoxide hydrolase is elevated in Alzheimer's hippocampus and induced by exogenous beta-amyloid and trimethyl-tin. The European Journal of Neuroscience. 23: 2027-34. PMID 16630050 DOI: 10.1111/J.1460-9568.2006.04724.X  0.407
2006 Espinosa PS, Kryscio RJ, Mendiondo MS, Schmitt FA, Wekstein DR, Markesbery WR, Smith CD. Alzheimer's disease and head circumference. Journal of Alzheimer's Disease : Jad. 9: 77-80. PMID 16627937 DOI: 10.3233/Jad-2006-9108  0.466
2006 Smith JL, Xiong S, Markesbery WR, Lovell MA. Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain. Neuroscience. 140: 879-88. PMID 16580781 DOI: 10.1016/J.Neuroscience.2006.02.049  0.421
2006 Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology. 66: 828-32. PMID 16567698 DOI: 10.1212/01.Wnl.0000203264.71880.45  0.335
2006 Mohmmad Abdul H, Sultana R, Keller JN, St Clair DK, Markesbery WR, Butterfield DA. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. Journal of Neurochemistry. 96: 1322-35. PMID 16478525 DOI: 10.1111/J.1471-4159.2005.03647.X  0.391
2006 Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiology of Disease. 22: 223-32. PMID 16466929 DOI: 10.1016/J.Nbd.2005.11.002  0.438
2006 Wang J, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. Journal of Neurochemistry. 96: 825-32. PMID 16405502 DOI: 10.1111/J.1471-4159.2005.03615.X  0.386
2006 Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Archives of Neurology. 63: 38-46. PMID 16401735 DOI: 10.1001/Archneur.63.1.38  0.384
2006 Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiology of Disease. 22: 76-87. PMID 16378731 DOI: 10.1016/J.Nbd.2005.10.004  0.456
2006 Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiology of Aging. 27: 1564-76. PMID 16271804 DOI: 10.1016/J.Neurobiolaging.2005.09.021  0.448
2006 Smith CD, Wekstein DR, Markesbery WR, Frye CA. 3alpha,5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. Psychopharmacology. 186: 481-5. PMID 16231167 DOI: 10.1007/S00213-005-0186-1  0.367
2006 Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiology of Aging. 27: 1094-9. PMID 15993986 DOI: 10.1016/J.Neurobiolaging.2005.06.004  0.458
2006 Lovell MA, Geiger H, Van Zant GE, Lynn BC, Markesbery WR. Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. Neurobiology of Aging. 27: 909-17. PMID 15979211 DOI: 10.1016/J.Neurobiolaging.2005.05.004  0.435
2006 Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, Butterfield DA. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiology of Aging. 27: 918-25. PMID 15950321 DOI: 10.1016/J.Neurobiolaging.2005.05.005  0.45
2006 Gearing M, Markesbery WR, Poon LW, Burgess M, Green RC. P1-158: Alzheimer's disease in centenarians: Clinicopathologic correlations in the georgia centenarian study Alzheimer's & Dementia. 2: S142-S142. DOI: 10.1016/J.Jalz.2006.05.534  0.383
2006 Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Cooper G, Markesbery WR. IC-P-040: Structural image data from normals grouped by six-year cognitive outcome: MCI/AD conversion vs. normal Alzheimer's & Dementia. 2: S670-S671. DOI: 10.1016/J.Jalz.2006.05.2245  0.335
2006 Mendiondo MS, Caban-Holt AM, Saylor CR, Runyons C, Kryscio R, Markesbery WR, Schmitt FA. P3-007: Cognitive screening in the antioxidant AD prevention (PREADVISE) trial: Concordance of MIS and CERAD Alzheimer's & Dementia. 2: S373-S374. DOI: 10.1016/J.Jalz.2006.05.1274  0.351
2005 White L, Small BJ, Petrovitch H, Ross GW, Masaki K, Abbott RD, Hardman J, Davis D, Nelson J, Markesbery W. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. Journal of Geriatric Psychiatry and Neurology. 18: 224-7. PMID 16306244 DOI: 10.1177/0891988705281872  0.438
2005 Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Annals of Neurology. 58: 730-5. PMID 16240347 DOI: 10.1002/Ana.20629  0.426
2005 Russo R, Borghi R, Markesbery W, Tabaton M, Piccini A. Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. Febs Letters. 579: 6027-30. PMID 16226260 DOI: 10.1016/J.Febslet.2005.09.054  0.462
2005 Ding Q, Markesbery WR, Chen Q, Li F, Keller JN. Ribosome dysfunction is an early event in Alzheimer's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 9171-5. PMID 16207876 DOI: 10.1523/Jneurosci.3040-05.2005  0.464
2005 Lovell MA, Smith JL, Xiong S, Markesbery WR. Alterations in zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive impairment, early, and late-stage Alzheimer's disease. Neurotoxicity Research. 7: 265-71. PMID 16179263 DOI: 10.1007/Bf03033884  0.48
2005 Lovell MA, Markesbery WR. Ectopic expression of Musashi-1 in Alzheimer disease and Pick disease. Journal of Neuropathology and Experimental Neurology. 64: 675-80. PMID 16106215 DOI: 10.1097/01.Jnen.0000173891.17176.5B  0.437
2005 Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. Journal of Neurochemistry. 93: 953-62. PMID 15857398 DOI: 10.1111/J.1471-4159.2005.03053.X  0.405
2005 Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 64: 1152-6. PMID 15824339 DOI: 10.1212/01.Wnl.0000156156.13641.Ba  0.458
2005 Lovell MA, Xiong S, Markesbery WR, Lynn BC. Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide. Neurochemical Research. 30: 113-22. PMID 15756939 DOI: 10.1007/S11064-004-9692-5  0.334
2005 Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxidants & Redox Signaling. 7: 269-75. PMID 15650414 DOI: 10.1089/Ars.2005.7.269  0.426
2005 Riley KP, Snowdon DA, Desrosiers MF, Markesbery WR. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiology of Aging. 26: 341-7. PMID 15639312 DOI: 10.1016/J.Neurobiolaging.2004.06.019  0.368
2005 Ertekin-Taner N, Ronald J, Feuk L, Prince J, Tucker M, Younkin L, Hella M, Jain S, Hackett A, Scanlin L, Kelly J, Kihiko-Ehman M, Neltner M, Hersh L, Kindy M, ... Markesbery W, et al. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Human Molecular Genetics. 14: 447-60. PMID 15615772 DOI: 10.1093/Hmg/Ddi041  0.327
2005 Petrovitch H, Ross GW, Steinhorn SC, Abbott RD, Markesbery W, Davis D, Nelson J, Hardman J, Masaki K, Vogt MR, Launer L, White LR. AD lesions and infarcts in demented and non-demented Japanese-American men. Annals of Neurology. 57: 98-103. PMID 15562458 DOI: 10.1002/Ana.20318  0.371
2005 Runyons CR, Schmitt FA, Caban-Holt A, Kryscio RJ, Mendiondo MS, Markesbery WR. [P-208]: Antioxidants for the prevention of dementia: Overview of the preadvise trial Alzheimer's & Dementia. 1: S74-S74. DOI: 10.1016/J.Jalz.2005.06.266  0.302
2005 Schmitt FA, Markesbery WR, Kryscio RJ, Caban-Holt A, Cooper G, Smith C, Wekstein D, Davis DG. [P-032]: Neuropathological and memory changes in transitions between normal aging, MCI, and mild Alzheimer's disease Alzheimer's & Dementia. 1: S18-S19. DOI: 10.1016/J.Jalz.2005.06.094  0.37
2004 Lovell MA, Xiong S, Xie C, Davies P, Markesbery WR. Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. Journal of Alzheimer's Disease : Jad. 6: 659-71; discussion 6. PMID 15665406 DOI: 10.3233/Jad-2004-6610  0.331
2004 Kashon ML, Ross GW, O'Callaghan JP, Miller DB, Petrovitch H, Burchfiel CM, Sharp DS, Markesbery WR, Davis DG, Hardman J, Nelson J, White LR. Associations of cortical astrogliosis with cognitive performance and dementia status. Journal of Alzheimer's Disease : Jad. 6: 595-604; discussion . PMID 15665400 DOI: 10.3233/Jad-2004-6604  0.423
2004 Jorm AF, Masaki KH, Davis DG, Hardman J, Nelson J, Markesbery WR, Petrovitch H, Ross GW, White LR. Memory complaints in nondemented men predict future pathologic diagnosis of Alzheimer disease. Neurology. 63: 1960-1. PMID 15557525 DOI: 10.1212/01.Wnl.0000144348.70643.F2  0.365
2004 Ricciarelli R, D'Abramo C, Zingg JM, Giliberto L, Markesbery W, Azzi A, Marinari UM, Pronzato MA, Tabaton M. CD36 overexpression in human brain correlates with beta-amyloid deposition but not with Alzheimer's disease. Free Radical Biology & Medicine. 36: 1018-24. PMID 15059642 DOI: 10.1016/J.Freeradbiomed.2004.01.007  0.415
2004 Mortimer JA, Gosche KM, Riley KP, Markesbery WR, Snowdon DA. Delayed recall, hippocampal volume and Alzheimer neuropathology: findings from the Nun Study. Neurology. 62: 428-32. PMID 14872025 DOI: 10.1212/01.Wnl.0000106463.66966.65  0.38
2004 Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proceedings of the National Academy of Sciences of the United States of America. 101: 2173-8. PMID 14769913 DOI: 10.1073/Pnas.0308512100  0.397
2004 Kryscio RJ, Mendiondo MS, Schmitt FA, Markesbery WR. Designing a large prevention trial: statistical issues. Statistics in Medicine. 23: 285-96. PMID 14716729 DOI: 10.1002/Sim.1716  0.363
2004 Piccini A, Vitali A, Borghi R, Giliberto L, Patrone E, D'Arrigo C, Saido T, Markesbery W, Gambetti P, Tabaton M. P1-167 Soluble abeta shows a different composition in normal aging and Alzheimer's disease Neurobiology of Aging. 25: S143. DOI: 10.1016/S0197-4580(04)80480-9  0.39
2004 Lovell MA, Lynn BC, Markesbery WR. O2-04-05 Proteomic analysis of mitochondria from control, early, and late state Alzheimer's disease subjects Neurobiology of Aging. 25: S39-S40. DOI: 10.1016/S0197-4580(04)80131-3  0.35
2003 Lovell MA, Xie C, Xiong S, Markesbery WR. Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Brain Research. 983: 84-96. PMID 12914969 DOI: 10.1016/S0006-8993(03)03032-4  0.381
2003 Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. Journal of Alzheimer's Disease : Jad. 5: 229-39. PMID 12897407 DOI: 10.3233/Jad-2003-5306  0.328
2003 Mortimer JA, Snowdon DA, Markesbery WR. Head circumference, education and risk of dementia: findings from the Nun Study. Journal of Clinical and Experimental Neuropsychology. 25: 671-9. PMID 12815504 DOI: 10.1076/Jcen.25.5.671.14584  0.358
2003 Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. Journal of Neurochemistry. 85: 1394-401. PMID 12787059 DOI: 10.1046/J.1471-4159.2003.01786.X  0.436
2003 Pulliam JF, Jennings CD, Kryscio RJ, Davis DG, Wilson D, Montine TJ, Schmitt FA, Markesbery WR. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 119: 48-53. PMID 12707938 DOI: 10.1002/Ajmg.B.10069  0.449
2003 Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, Woodward J, Guo Z, Fu W, Kryscio R, Wekstein D, Smith C, Markesbery WR, Mattson MP. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Medicine. 3: 29-39. PMID 12665674 DOI: 10.1385/Nmm:3:1:29  0.375
2002 White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, Masaki K, Launer L, Markesbery WR. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Annals of the New York Academy of Sciences. 977: 9-23. PMID 12480729 DOI: 10.1111/J.1749-6632.2002.Tb04794.X  0.351
2002 Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. Journal of Neurochemistry. 82: 1524-32. PMID 12354300 DOI: 10.1046/J.1471-4159.2002.01103.X  0.312
2002 Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radical Biology & Medicine. 33: 620-6. PMID 12208348 DOI: 10.1016/S0891-5849(02)00807-9  0.362
2002 Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Biology & Medicine. 33: 562-71. PMID 12160938 DOI: 10.1016/S0891-5849(02)00914-0  0.421
2002 Riley KP, Snowdon DA, Markesbery WR. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Annals of Neurology. 51: 567-77. PMID 12112102 DOI: 10.1002/Ana.10161  0.413
2002 Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology. 58: 1476-82. PMID 12034782 DOI: 10.1212/Wnl.58.10.1476  0.383
2002 Williamson KS, Gabbita SP, Mou S, West M, Pye QN, Markesbery WR, Cooney RV, Grammas P, Reimann-Philipp U, Floyd RA, Hensley K. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 6: 221-7. PMID 11890747 DOI: 10.1006/Niox.2001.0399  0.431
2002 Lovell MA, Robertson JD, Buchholz BA, Xie C, Markesbery WR. Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. Neurobiology of Aging. 23: 179-86. PMID 11804701 DOI: 10.1016/S0197-4580(01)00281-0  0.402
2002 Robertson JD, Crafford AM, Markesbery WR, Lovell MA. Disruption of zinc homeostasis in Alzheimer's disease Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions With Materials and Atoms. 189: 454-458. DOI: 10.1016/S0168-583X(01)01124-7  0.456
2001 Ko LW, Sheu KF, Thaler HT, Markesbery WR, Blass JP. Selective loss of KGDHC-enriched neurons in Alzheimer temporal cortex: does mitochondrial variation contribute to selective vulnerability? Journal of Molecular Neuroscience : Mn. 17: 361-9. PMID 11859932 DOI: 10.1385/Jmn:17:3:361  0.367
2001 Reich EE, Markesbery WR, Roberts LJ, Swift LL, Morrow JD, Montine TJ. Quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Advances in Experimental Medicine and Biology. 500: 253-6. PMID 11764949 DOI: 10.1007/978-1-4615-0667-6_39  0.352
2001 Schmitt FA, Wetherby MM, Wekstein DR, Dearth CM, Markesbery WR. Brain donation in normal aging: procedures, motivations, and donor characteristics from the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project. The Gerontologist. 41: 716-22. PMID 11723339 DOI: 10.1093/Geront/41.6.716  0.309
2001 Picklo MJ, Olson SJ, Hayes JD, Markesbery WR, Montine TJ. Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease. Brain Research. 916: 229-38. PMID 11597610 DOI: 10.1016/S0006-8993(01)02897-9  0.413
2001 Petrovitch H, White LR, Ross GW, Steinhorn SC, Li CY, Masaki KH, Davis DG, Nelson J, Hardman J, Curb JD, Blanchette PL, Launer LJ, Yano K, Markesbery WR. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology. 57: 226-34. PMID 11468306 DOI: 10.1212/WNL.57.2.226  0.307
2001 Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. Journal of Neurochemistry. 78: 413-6. PMID 11461977 DOI: 10.1046/J.1471-4159.2001.00451.X  0.407
2001 Picklo MJ, Olson SJ, Markesbery WR, Montine TJ. Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. Journal of Neuropathology and Experimental Neurology. 60: 686-95. PMID 11444797 DOI: 10.1093/Jnen/60.7.686  0.444
2001 Lauderback CM, Hackett JM, Keller JN, Varadarajan S, Szweda L, Kindy M, Markesbery WR, Butterfield DA. Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1-40): implications for Alzheimer's disease. Biochemistry. 40: 2548-54. PMID 11327877 DOI: 10.1021/Bi002312K  0.384
2001 Aksenov MY, Markesbery WR. Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. Neuroscience Letters. 302: 141-5. PMID 11290407 DOI: 10.1016/S0304-3940(01)01636-6  0.461
2001 Lovell MA, Markesbery WR. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Archives of Neurology. 58: 392-6. PMID 11255442 DOI: 10.1001/Archneur.58.3.392  0.422
2001 Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. Neuroscience. 103: 373-83. PMID 11246152 DOI: 10.1016/S0306-4522(00)00580-7  0.306
2001 Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiology of Aging. 22: 187-94. PMID 11182468 DOI: 10.1016/S0197-4580(00)00235-9  0.476
2001 Reich EE, Markesbery WR, Roberts LJ, Swift LL, Morrow JD, Montine TJ. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. The American Journal of Pathology. 158: 293-7. PMID 11141503 DOI: 10.1016/S0002-9440(10)63968-5  0.364
2001 Markesbery WR. Use of bomb pulse 14C to age senile plaques and neurofibrillary tangles in the Alzheimer's disease brain Journal of Radioanalytical and Nuclear Chemistry. 249: 443-447. DOI: 10.1023/A:1013299426601  0.392
2000 Lovell MA, Xie C, Markesbery WR. Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radical Biology & Medicine. 29: 714-20. PMID 11053772 DOI: 10.1016/S0891-5849(00)00346-4  0.408
2000 Rulon LL, Robertson JD, Lovell MA, Deibel MA, Ehmann WD, Markesbery WR. Serum zinc levels and Alzheimer's disease Biological Trace Element Research. 75: 79-85. PMID 11051598 DOI: 10.1385/Bter:75:1-3:79  0.442
2000 Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology. 55: 370-6. PMID 10932270 DOI: 10.1212/Wnl.55.3.370  0.459
2000 Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. Journal of Neurochemistry. 75: 436-9. PMID 10854289 DOI: 10.1046/J.1471-4159.2000.0750436.X  0.469
2000 Aksenov M, Aksenova M, Butterfield DA, Markesbery WR. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. Journal of Neurochemistry. 74: 2520-7. PMID 10820214 DOI: 10.1046/j.1471-4159.2000.0742520.x  0.344
2000 Snowdon DA, Greiner LH, Markesbery WR. Linguistic ability in early life and the neuropathology of Alzheimer's disease and cerebrovascular disease. Findings from the Nun Study. Annals of the New York Academy of Sciences. 903: 34-8. PMID 10818486 DOI: 10.1111/J.1749-6632.2000.Tb06347.X  0.397
2000 Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiology of Aging. 21: 57-62. PMID 10794849 DOI: 10.1016/S0197-4580(00)00106-8  0.374
2000 White LR, Petrovitch H, Ross GW, Masaki K, Hardman J, Nelson J, Davis D, Markesbery W. Brain aging and midlife tofu consumption. Journal of the American College of Nutrition. 19: 242-55. PMID 10763906 DOI: 10.1080/07315724.2000.10718923  0.315
2000 Keller JN, Lauderback CM, Butterfield DA, Kindy MS, Yu J, Markesbery WR. Amyloid beta-peptide effects on synaptosomes from apolipoprotein E-deficient mice. Journal of Neurochemistry. 74: 1579-86. PMID 10737615 DOI: 10.1046/J.1471-4159.2000.0741579.X  0.306
2000 Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. The American Journal of Clinical Nutrition. 71: 993-8. PMID 10731508 DOI: 10.1093/Ajcn/71.4.993  0.431
2000 Keller JN, Hanni KB, Markesbery WR. Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mechanisms of Ageing and Development. 113: 61-70. PMID 10708250 DOI: 10.1016/S0047-6374(99)00101-3  0.303
2000 Lovell MA, Xie C, Gabbita SP, Markesbery WR. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radical Biology & Medicine. 28: 418-27. PMID 10699754 DOI: 10.1016/S0891-5849(99)00258-0  0.472
2000 Smith CD, Snowdon DA, Wang H, Markesbery WR. White matter volumes and periventricular white matter hyperintensities in aging and dementia. Neurology. 54: 838-42. PMID 10690973 DOI: 10.1212/Wnl.54.4.838  0.308
2000 Lovell MA, Xie C, Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Research. 855: 116-23. PMID 10650137 DOI: 10.1016/S0006-8993(99)02335-5  0.429
2000 Mortimer JA, Markesbery WR, Snowdon DA. Apolipoprotein E-ε4 as a risk factor for Alzheimer and non-Alzheimer'sdementias: Findings from the nun study Neurobiology of Aging. 21: 32-33. DOI: 10.1016/S0197-4580(00)82822-5  0.357
2000 Petrovitch H, Steinhorn SC, Ross GW, Markesbery WR, Davis DG, Hardman J, Launer LJ, White LR. Neurofibrillary tangles, neuritic plaques, and cerebrovascular lesions at death among demented and cognitively normal Japanese-American men Neurobiology of Aging. 21: 57. DOI: 10.1016/S0197-4580(00)82479-3  0.312
1999 Bassett CN, Neely MD, Sidell KR, Markesbery WR, Swift LL, Montine TJ. Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo. Lipids. 34: 1273-80. PMID 10652986 DOI: 10.1007/S11745-999-0478-1  0.384
1999 Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Disease and Associated Disorders. 13: 226-31. PMID 10609672 DOI: 10.1097/00002093-199910000-00009  0.481
1999 Markesbery WR. The role of oxidative stress in Alzheimer disease. Archives of Neurology. 56: 1449-52. PMID 10593298 DOI: 10.1001/Archneur.56.12.1449  0.374
1999 Keller JN, Hanni KB, Markesbery WR. 4-hydroxynonenal increases neuronal susceptibility to oxidative stress. Journal of Neuroscience Research. 58: 823-30. PMID 10583913 DOI: 10.1002/(Sici)1097-4547(19991215)58:6<823::Aid-Jnr9>3.0.Co;2-T  0.315
1999 Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ, Morrow JD. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 53: 1495-8. PMID 10534257 DOI: 10.1212/Wnl.53.7.1495  0.325
1999 Aksenova MV, Aksenov MY, Markesbery WR, Butterfield DA. Aging in a dish: age-dependent changes of neuronal survival, protein oxidation, and creatine kinase BB expression in long-term hippocampal cell culture. Journal of Neuroscience Research. 58: 308-17. PMID 10502287 DOI: 10.1002/(Sici)1097-4547(19991015)58:2<308::Aid-Jnr11>3.0.Co;2-#  0.316
1999 Gabbita SP, Aksenov MY, Lovell MA, Markesbery WR. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. Journal of Neurochemistry. 73: 1660-6. PMID 10501213 DOI: 10.1046/J.1471-4159.1999.0731660.X  0.466
1999 Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ, Morrow JD. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. The American Journal of Pathology. 155: 863-8. PMID 10487843 DOI: 10.1016/S0002-9440(10)65185-1  0.445
1999 Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, Markesbery WR. The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease. Neurochemical Research. 24: 767-74. PMID 10447460 DOI: 10.1023/A:1020783614031  0.401
1999 Keller JN, Hanni KB, Markesbery WR. Oxidized low-density lipoprotein induces neuronal death: implications for calcium, reactive oxygen species, and caspases. Journal of Neurochemistry. 72: 2601-9. PMID 10349872 DOI: 10.1046/J.1471-4159.1999.0722601.X  0.32
1999 Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. Journal of Neuropathology and Experimental Neurology. 58: 376-88. PMID 10218633 DOI: 10.1097/00005072-199904000-00008  0.426
1999 Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G. p38 kinase is activated in the Alzheimer's disease brain. Journal of Neurochemistry. 72: 2053-8. PMID 10217284 DOI: 10.1046/J.1471-4159.1999.0722053.X  0.382
1999 Goedert M, Spillantini MG, Crowther RA, Chen SG, Parchi P, Tabaton M, Lanska DJ, Markesbery WR, Wilhelmsen KC, Dickson DW, Petersen RB, Gambetti P. Tau gene mutation in familial progressive subcortical gliosis. Nature Medicine. 5: 454-7. PMID 10202939 DOI: 10.1038/7454  0.32
1999 Lovell MA, Xie C, Markesbery WR. Protection against amyloid beta peptide toxicity by zinc. Brain Research. 823: 88-95. PMID 10095015 DOI: 10.1016/S0006-8993(99)01114-2  0.316
1999 Saxe SR, Wekstein MW, Kryscio RJ, Henry RG, Cornett CR, Snowdon DA, Grant FT, Schmitt FA, Donegan SJ, Wekstein DR, Ehmann WD, Markesbery WR. Alzheimer's disease, dental amalgam and mercury. Journal of the American Dental Association (1939). 130: 191-9. PMID 10036842 DOI: 10.14219/Jada.Archive.1999.0168  0.31
1999 Aksenova MV, Aksenov MY, Payne RM, Trojanowski JQ, Schmidt ML, Carney JM, Butterfield DA, Markesbery WR. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dementia and Geriatric Cognitive Disorders. 10: 158-65. PMID 10026391 DOI: 10.1159/000017098  0.544
1999 Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathology (Zurich, Switzerland). 9: 133-46. PMID 9989456 DOI: 10.1111/J.1750-3639.1999.Tb00215.X  0.456
1999 Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. Journal of Neurochemistry. 72: 771-6. PMID 9930752 DOI: 10.1046/J.1471-4159.1999.0720771.X  0.401
1999 Smith CD, Malcein M, Meurer K, Schmitt FA, Markesbery WR, Pettigrew LC. MRI temporal lobe volume measures and neuropsychologic function in Alzheimer's disease. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 9: 2-9. PMID 9922716 DOI: 10.1111/Jon1999912  0.387
1998 Yatin SM, Aksenova M, Aksenov M, Markesbery WR, Aulick T, Butterfield DA. Temporal relations among amyloid beta-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses. Journal of Molecular Neuroscience : Mn. 11: 183-97. PMID 10344789 DOI: 10.1385/Jmn:11:3:183  0.369
1998 Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, Markesbery WR. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. Journal of Molecular Neuroscience : Mn. 11: 151-64. PMID 10096042 DOI: 10.1385/Jmn:11:2:151  0.399
1998 Lovell MA, Xie C, Markesbery WR. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology. 51: 1562-6. PMID 9855502 DOI: 10.1212/Wnl.51.6.1562  0.47
1998 Xie C, Lovell MA, Markesbery WR. Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity. Free Radical Biology & Medicine. 25: 979-88. PMID 9840744 DOI: 10.1016/S0891-5849(98)00186-5  0.306
1998 Zhang D, Dhillon H, Prasad MR, Markesbery WR. Regional levels of brain phospholipase Cgamma in Alzheimer's disease. Brain Research. 811: 161-5. PMID 9804940 DOI: 10.1016/S0006-8993(98)00935-4  0.417
1998 Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. Journal of Neurochemistry. 71: 2034-40. PMID 9798928 DOI: 10.1046/J.1471-4159.1998.71052034.X  0.462
1998 Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 8126-32. PMID 9763459 DOI: 10.1523/Jneurosci.18-20-08126.1998  0.453
1998 Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Annals of Neurology. 44: 410-3. PMID 9749613 DOI: 10.1002/Ana.410440322  0.428
1998 Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. Journal of the Neurological Sciences. 158: 47-52. PMID 9667777 DOI: 10.1016/S0022-510X(98)00092-6  0.388
1998 Lanska DJ, Markesbery WR, Cochran E, Bennett D, Lanska MJ, Cohen M. Late-onset sporadic progressive subcortical gliosis. Journal of the Neurological Sciences. 157: 143-7. PMID 9619636 DOI: 10.1016/S0022-510X(98)00063-X  0.436
1998 Bruce-Keller AJ, Li YJ, Lovell MA, Kraemer PJ, Gary DS, Brown RR, Markesbery WR, Mattson MP. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. Journal of Neuropathology and Experimental Neurology. 57: 257-67. PMID 9600218 DOI: 10.1097/00005072-199803000-00007  0.381
1998 Tekirian TL, Saido TC, Markesbery WR, Russell MJ, Wekstein DR, Patel E, Geddes JW. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. Journal of Neuropathology and Experimental Neurology. 57: 76-94. PMID 9600199 DOI: 10.1097/00005072-199801000-00009  0.375
1998 Montine KS, Reich E, Neely MD, Sidell KR, Olson SJ, Markesbery WR, Montine TJ. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. Journal of Neuropathology and Experimental Neurology. 57: 415-25. PMID 9596412 DOI: 10.1097/00005072-199805000-00005  0.474
1998 Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiology of Aging. 19: 33-6. PMID 9562500 DOI: 10.1016/S0197-4580(98)00009-8  0.484
1998 Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochemical Research. 23: 81-8. PMID 9482271 DOI: 10.1023/A:1022457605436  0.401
1997 Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiology of Aging. 18: 457-61. PMID 9390770 DOI: 10.1016/S0197-4580(97)00108-5  0.454
1997 Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, Davis DG, Markesbery WR. Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiology of Aging. 18: S99-105. PMID 9330997 DOI: 10.1016/S0197-4580(97)00063-8  0.405
1997 Markesbery WR. Neuropathological criteria for the diagnosis of Alzheimer's disease. Neurobiology of Aging. 18: S13-9. PMID 9330980 DOI: 10.1016/S0197-4580(97)00064-X  0.423
1997 Ball M, Braak H, Coleman P, Dickson D, Duyckaerts C, Gambetti P, Hansen L, Hyman B, Jellinger K, Markesbery W, Perl D, Powers J, Price J, Trojanowski JQ, Wisniewski H, et al. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease Neurobiology of Aging. 18: S1-S2. PMID 9330978 DOI: 10.1016/S0197-4580(97)00057-2  0.422
1997 Aksenov MY, Aksenova MV, Payne RM, Smith CD, Markesbery WR, Carney JM. The expression of creatine kinase isoenzymes in neocortex of patients with neurodegenerative disorders: Alzheimer's and Pick's disease. Experimental Neurology. 146: 458-65. PMID 9270056 DOI: 10.1006/Exnr.1997.6550  0.397
1997 Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ. 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. Journal of Neuropathology and Experimental Neurology. 56: 866-71. PMID 9258256 DOI: 10.1097/00005072-199708000-00004  0.494
1997 Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. Jama. 277: 813-7. PMID 9052711 DOI: 10.1001/Jama.1997.03540340047031  0.456
1997 Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. Journal of Neurochemistry. 68: 255-64. PMID 8978733 DOI: 10.1046/J.1471-4159.1997.68010255.X  0.317
1996 Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. Journal of the Neurological Sciences. 143: 137-42. PMID 8981312 DOI: 10.1016/S0022-510X(96)00203-1  0.427
1996 Tekirian TL, Cole GM, Russell MJ, Yang F, Wekstein DR, Patel E, Snowdon DA, Markesbery WR, Geddes JW. Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains. Neurobiology of Aging. 17: 249-57. PMID 8744406 DOI: 10.1016/0197-4580(95)02062-4  0.316
1996 Hensley K, Butterfield DA, Hall N, Cole P, Subramaniam R, Mark R, Mattson MP, Markesbery WR, Harris ME, Aksenov M. Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Annals of the New York Academy of Sciences. 786: 120-34. PMID 8687014 DOI: 10.1111/J.1749-6632.1996.Tb39057.X  0.328
1996 Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. Jama. 275: 528-32. PMID 8606473 DOI: 10.1001/Jama.1996.03530310034029  0.345
1996 Geddes JW, Snowdon DA, Soultanian NS, Tekirian TL, Riley KP, Ashford JW, Davis DG, Markesbery WR. BRAAK STAGES III-IV OF ALZHEIMER-RELATED NEUROPATHOLOGY ARE ASSOCIATED WITH MILD MEMORY LOSS, STAGES V-VI ARE ASSOCIATED WITH DEMENTIA Journal of Neuropathology and Experimental Neurology. 55: 617. DOI: 10.1097/00005072-199605000-00059  0.314
1995 Tully CL, Snowdon DA, Markesbery WR. Serum zinc, senile plaques, and neurofibrillary tangles: findings from the Nun Study. Neuroreport. 6: 2105-8. PMID 8595180 DOI: 10.1097/00001756-199511000-00002  0.388
1995 Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45: 1594-601. PMID 7644059 DOI: 10.1212/Wnl.45.8.1594  0.445
1995 Kindy MS, de Beer FC, Markesbery WR, Pras M, Aksentijevich I, Kastner D, Kyle R, Solomon A, Woo P. Apolipoprotein e genotypes in AA and AL amyloidoses Amyloid. 2: 159-162. DOI: 10.3109/13506129509036919  0.43
1995 Cornett CR, Samudralwar DL, Ehmann WD, Markesbery WR. Sensitivity improvements in the determination of mercury in biological tissues by neutron activation analysis Journal of Radioanalytical and Nuclear Chemistry Articles. 195: 117-121. DOI: 10.1007/Bf02036480  0.33
1995 Lovell MA, Robertson JD, Ehmann WD, Markesbery WR, Teesdale WJ, Campbell JL. Comparison of laser microprobe mass spectrometry (LMMS) and micro particle induced X-ray emission (micro-PIXE) for the analysis of senile plaques in Alzheimer's disease: A preliminary study Journal of Radioanalytical and Nuclear Chemistry Articles. 195: 7-12. DOI: 10.1007/Bf02036467  0.336
1994 Lanska DJ, Currier RD, Cohen M, Gambetti P, Smith EE, Bebin J, Jackson JF, Whitehouse PJ, Markesbery WR. Familial progressive subcortical gliosis. Neurology. 44: 1633-43. PMID 7936288 DOI: 10.1212/Wnl.44.9.1633  0.358
1994 Kittur S, Hoh J, Endo H, Tourtellotte W, Weeks BS, Markesbery W, Adler W. Cytoskeletal neurofilament gene expression in brain tissue from Alzheimer's disease patients. I. Decrease in NF-L and NF-M message. Journal of Geriatric Psychiatry and Neurology. 7: 153-8. PMID 7522458 DOI: 10.1177/089198879400700305  0.371
1994 Tandon L, Ni B-, Ding XX, Ehmann WD, Kasarskis EJ, Markesbery WR. RNAA for arsenic, cadmium, copper, and molybdenum in CNS tissues from subjects with age-related neurodegenerative diseases Journal of Radioanalytical and Nuclear Chemistry Articles. 179: 331-339. DOI: 10.1007/Bf02040168  0.373
1993 Smith CD, Gallenstein LG, Layton WJ, Kryscio RJ, Markesbery WR. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease. Neurobiology of Aging. 14: 85-92. PMID 8450937 DOI: 10.1016/0197-4580(93)90026-8  0.431
1993 Mattson MP, Lovell MA, Ehmann WD, Markesbery WR. Comparison of the effects of elevated intracellular aluminum and calcium levels on neuronal survival and tau immunoreactivity. Brain Research. 602: 21-31. PMID 8448655 DOI: 10.1016/0006-8993(93)90236-G  0.303
1993 Markesbery WR, Wang HZ, Kowall NW, Kosik KS, McKee AC. Morphometric image analysis of neuropil threads in Alzheimer's disease. Neurobiology of Aging. 14: 303-7. PMID 8367011 DOI: 10.1016/0197-4580(93)90115-R  0.45
1993 Hamill RW, Markesbery WR, McDaniel K, Coleman PD. Characterization of brain samples in studies of aging, Alzheimer's, and other neurodegenerative diseases. Neurobiology of Aging. 14: 539-45. PMID 8295656 DOI: 10.1016/0197-4580(93)90037-C  0.457
1993 Lovell MA, Ehmann WD, Markesbery WR. Laser microprobe analysis of brain aluminum in Alzheimer's disease. Annals of Neurology. 33: 36-42. PMID 8257483 DOI: 10.1002/Ana.410330107  0.41
1993 Carpenter AF, Carpenter PW, Markesbery WR. Morphometric analysis of microglia in Alzheimer's disease. Journal of Neuropathology and Experimental Neurology. 52: 601-8. PMID 8229079 DOI: 10.1097/00005072-199311000-00007  0.443
1992 Russell MJ, White R, Patel E, Markesbery WR, Watson CR, Geddes JW. Familial influence on plaque formation in the beagle brain. Neuroreport. 3: 1093-6. PMID 1493222 DOI: 10.1097/00001756-199212000-00015  0.445
1992 Kittur SD, Endo H, Adler WH, Martin GR, Markesbery WR, Kleinman HK, Weeks BS. Alzheimer disease brain extract stimulates branching of laminin-mediated neuronal processes. Alzheimer Disease and Associated Disorders. 6: 103-10. PMID 1389079  0.315
1992 Smith CD, Carney JM, Tatsumo T, Stadtman ER, Floyd RA, Markesbery WR. Protein oxidation in aging brain. Annals of the New York Academy of Sciences. 663: 110-9. PMID 1362341 DOI: 10.1111/J.1749-6632.1992.Tb38654.X  0.307
1992 DeKosky ST, Harbaugh RE, Schmitt FA, Bakay RA, Chui HC, Knopman DS, Reeder TM, Shetter AG, Senter HJ, Markesbery WR. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Annals of Neurology. 32: 625-32. PMID 1360195 DOI: 10.1002/Ana.410320505  0.417
1992 Sparks DL, Hunsaker JC, Slevin JT, DeKosky ST, Kryscio RJ, Markesbery WR. Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert (nbM): normal age-related changes and the effect of heart disease and Alzheimer's disease. Annals of Neurology. 31: 611-20. PMID 1355334 DOI: 10.1002/Ana.410310608  0.337
1992 Davis DG, Wang HZ, Markesbery WR. Image analysis of neuropil threads in Alzheimer's, Pick's, diffuse Lewy body disease and in progressive supranuclear palsy. Journal of Neuropathology and Experimental Neurology. 51: 594-600. PMID 1336541 DOI: 10.1097/00005072-199211000-00004  0.442
1991 Sparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick's disease. Archives of Neurology. 48: 796-9. PMID 1898253 DOI: 10.1001/Archneur.1991.00530200032014  0.357
1991 Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 88: 10540-3. PMID 1683703 DOI: 10.1073/Pnas.88.23.10540  0.432
1991 MARKESBERY WR. Textbook of Neuropathology Journal of Neuropathology and Experimental Neurology. 50: 516-517. DOI: 10.1097/00005072-199107000-00012  0.372
1990 Wenstrup D, Ehmann WD, Markesbery WR. Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain Research. 533: 125-31. PMID 2085723 DOI: 10.1016/0006-8993(90)91804-P  0.441
1990 Vance DE, Ehmann WD, Markesbery WR. A search for longitudinal variations in trace element levels in nails of Alzheimer's disease patients. Biological Trace Element Research. 26: 461-70. PMID 1704751 DOI: 10.1007/Bf02992701  0.43
1990 Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiology of Aging. 11: 601-7. PMID 1704106 DOI: 10.1016/0197-4580(90)90024-T  0.461
1989 Doebler JA, Rhoads RE, Anthony A, Markesbery WR. Neuronal RNA in Pick's and Alzheimer's diseases. Comparison of disease-susceptible and disease-resistant cortical areas. Archives of Neurology. 46: 134-7. PMID 2464984 DOI: 10.1001/Archneur.1989.00520380034009  0.368
1989 Wilson D, Markesbery WR, Clark DB. LOCALIZED PICK BODIES. BALLOON CELLS. AND NEOCORTICAL CHANGES OF ALZHEIMER TYPE IN A DEMENTED PATIENT WITH PROGRESSIVE SUPRANUCLEAR PALSY Journal of Neuropathology and Experimental Neurology. 48: 311. DOI: 10.1097/00005072-198905000-00038  0.33
1988 Sparks DL, DeKosky ST, Markesbery WR. Alzheimer's disease. Aminergic-cholinergic alterations in hypothalamus. Archives of Neurology. 45: 994-9. PMID 2901257 DOI: 10.1001/Archneur.1988.00520330084014  0.398
1988 Doebler JA, Markesbery WR, Anthony A, Scheff SW, Rhoads RE. Astrocyte RNA in relation to neuronal RNA depletion in Alzheimer's disease. Acta Neuropathologica. 75: 272-6. PMID 2450442 DOI: 10.1007/Bf00690535  0.359
1988 Doebler JA, Markesbery WR, Anthony A, Davies P, Scheff SW, Rhoads RE. Neuronal RNA in relation to Alz-50 immunoreactivity in Alzheimer's disease. Annals of Neurology. 23: 20-4. PMID 2449843 DOI: 10.1002/Ana.410230105  0.386
1987 Ehmann WD, Markesbery WR, Kasarskis EJ, Vance DE, Khare SS, Hord JD, Thompson CM. Applications of neutron activation analysis to the study of age-related neurological diseases. Biological Trace Element Research. 13: 19-33. PMID 24254662 DOI: 10.1007/Bf02796618  0.355
1987 Doebler JA, Markesbery WR, Anthony A, Rhoads RE. In situ analysis of neostriatal RNA and chromatin in Alzheimer's disease. Neurology. 37: 309-13. PMID 2433642 DOI: 10.1212/Wnl.37.2.309  0.377
1987 Doebler JA, Markesbery WR, Anthony A, Rhoads RE. Neuronal RNA in relation to neuronal loss and neurofibrillary pathology in the hippocampus in Alzheimer's disease. Journal of Neuropathology and Experimental Neurology. 46: 28-39. PMID 2432192 DOI: 10.1097/00005072-198701000-00003  0.356
1986 Sparks DL, Markesbery WR, Slevin JT. Alzheimer's disease: monoamines and spiperone binding reduced in nucleus basalis. Annals of Neurology. 19: 602-4. PMID 2425718 DOI: 10.1002/Ana.410190616  0.364
1985 Butterfield DA, Farmer BT, Markesbery WR. Alzheimer's disease: no alteration in the physical state of erythrocyte membrane glycoconjugates. Annals of Neurology. 18: 104-5. PMID 4037746 DOI: 10.1002/Ana.410180124  0.336
1985 DeKosky ST, Scheff SW, Markesbery WR. Laminar organization of cholinergic circuits in human frontal cortex in Alzheimer's disease and aging. Neurology. 35: 1425-31. PMID 4033925 DOI: 10.1212/Wnl.35.10.1425  0.421
1984 Ehmann WD, Alauddin M, Hossain TI, Markesbery WR. Brain trace elements in Pick's disease. Annals of Neurology. 15: 102-4. PMID 6712183 DOI: 10.1002/Ana.410150119  0.37
1982 Butterfield DA, Markesbery WR. Time-dependence of, and effects of inhibition and cellular aging on, chloride efflux across erythrocyte membranes in Huntington's disease. Journal of the Neurological Sciences. 57: 29-39. PMID 6296324 DOI: 10.1016/0022-510X(82)90108-3  0.311
1981 Butterfield DA, Markesbery WR. Huntington's disease: a generalized membrane defect. Life Sciences. 28: 1117-31. PMID 6262588 DOI: 10.1016/0024-3205(81)90689-5  0.32
1981 Markesbery WR, Ehmann WD, Hossain TI, Alauddin M, Goodin DT. 182 BRAIN TRACE ELEMENT LEVELS IN ALZHEIMERʼS DISEASE BY INSTRUMENTAL NEUTRON ACTIVATION ANALYSIS Journal of Neuropathology and Experimental Neurology. 40: 359. DOI: 10.1097/00005072-198105000-00189  0.314
1980 Butterfield DA, Markesbery WR. Specificity of biophysical and biochemical alterations in erythrocyte membranes in neurological disorders--Huntington's disease, Friedreich's ataxia, Alzheimer's disease, amyotrophic lateral sclerosis, and myotonic and duchenne muscular dystrophy. Journal of the Neurological Sciences. 47: 261-71. PMID 6251175 DOI: 10.1016/0022-510X(80)90010-6  0.356
1980 Markesbery WR, Leung PK, Butterfield DA. Spin label and biochemical studies of erythrocyte membranes in Alzheimer's disease Journal of the Neurological Sciences. 45: 323-330. PMID 6245187 DOI: 10.1016/0022-510X(80)90175-6  0.334
1979 Butterfield DA, Purdy MJ, Markesbery WR. Electron spin resonance, hematological, and deformability studies of erythrocytes from patients with Huntington's disease. Biochimica Et Biophysica Acta. 551: 452-8. PMID 217434 DOI: 10.1016/0005-2736(89)90020-5  0.312
1978 McIntosh GC, Jameson HD, Markesbery WR. Huntington disease associated with Alzheimer disease. Annals of Neurology. 3: 545-8. PMID 150253 DOI: 10.1002/ana.410030616  0.304
1977 Banta RG, Markesbery WR. Elevated manganese levels associated with dementia and extrapyramidal signs. Neurology. 27: 213-6. PMID 557755 DOI: 10.1212/Wnl.27.3.213  0.4
1977 Butterfield DA, Oeswein JQ, Markesbery WR. Electron spin resonance study of membrane protein alterations in erythrocytes in Huntington's disease. Nature. 267: 453-5. PMID 195214 DOI: 10.1038/267453A0  0.337
1976 Markesbery WR, Shield LK, Egel RT, Jameson HD. Late-infantile neuronal ceroid-lipofuscinosis. An ultrastructural study of lymphocyte inclusions. Archives of Neurology. 33: 630-5. PMID 183637 DOI: 10.1001/Archneur.1976.00500090036007  0.318
Show low-probability matches.